Literature DB >> 26613723

Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.

A Ghezzi1, E Mutta2, F Bianchi3, S Bonavita4, F Buttari5, A Caramma6, R Cavarretta7, D Centonze5, G C Coghe8, G Coniglio9, U Del Carro3, M T Ferrò10, M G Marrosu8, F Patti6, M Rovaris7, M Sparaco4, I Simone11, C Tortorella11, R Bergamaschi12.   

Abstract

Many guidelines are available for the management of lower urinary tract symptoms (LUTSs) in multiple sclerosis (MS) patients, but no agreement exists on the best approach for subjects without LUTSs. The objective of this study was to evaluate whether LUTSs can be detected in MS patients asymptomatic for urinary dysfunction, comparing three different tools [measure of post-void residual volume (PRV), bladder diary (BD), a focused questionnaire (IPSS)], and whether disability, disease duration and signs of pyramidal involvement are linked to their subclinical presence. 178 MS patients (118 women) have been included (mean age 41.2 years, mean disease duration 11.3 years, mean EDSS 2.2), and tested with the above-mentioned tools. PRV was abnormal in 14 subjects (7.8%), associated to abnormal findings at IPSS in 3 cases, at BD in 2 cases, at both in 1. BD was abnormal in 37 subjects (20.8%), with concomitant abnormal PRV in 2, abnormal IPSS in 10 cases, abnormal IPSS and BD in 1. IPSS was ≥ 9 in 43 subjects (24.1%). At least one test was abnormal in 76 patients (42.7%): 1 in 57 patients (32.0%), 2 in 17 (9.5%), and 3 tests in 2 (1.1%). Patients with at least one abnormal urinary variable, compared to patients without urinary abnormalities, had a more frequent pyramidal involvement (69.5 vs. 16.8%, χ(2) = 48.6, p < 0.00001), a more frequent occurrence of EDSS ≥2 (83.1 vs. 23.5%, χ(2) = 56.9, p < 0.00001), and a longer disease duration (15.7 ± 7.3 vs. 9.1 ± 7.1, t = 5.7, p < 0.00001). Asymptomatic LUTS were frequent but none of the tests used permitted to better identify asymptomatic patients.

Entities:  

Keywords:  Bladder diary; IPSS; Multiple sclerosis; Post-void residual volume; Urinary dysfunction

Mesh:

Year:  2015        PMID: 26613723     DOI: 10.1007/s10072-015-2415-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

Review 1.  Therapeutic strategies of urinary disorders in MS. Practice and algorithms.

Authors:  P Denys; V Phe; A Even; E Chartier-Kastler
Journal:  Ann Phys Rehabil Med       Date:  2014-06-04

2.  Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction.

Authors:  M W Nortvedt; T Riise; K M Myhr; A M Landtblom; A Bakke; H I Nyland
Journal:  Mult Scler       Date:  2001-08       Impact factor: 6.312

3.  The value of the Kurtzke Functional Systems Scales in predicting incomplete bladder emptying.

Authors:  K Kirchhof; C J Fowler
Journal:  Spinal Cord       Date:  2000-07       Impact factor: 2.772

Review 4.  Multiple sclerosis and the urologist.

Authors:  S E Litwiller; E M Frohman; P E Zimmern
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

5.  EAU guidelines on neurogenic lower urinary tract dysfunction.

Authors:  Manfred Stöhrer; Bertil Blok; David Castro-Diaz; Emanuel Chartier-Kastler; Giulio Del Popolo; Guus Kramer; Jürgen Pannek; Piotr Radziszewski; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2009-04-21       Impact factor: 20.096

6.  Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction.

Authors:  Marianna Vitkova; Jaroslav Rosenberger; Martina Krokavcova; Jarmila Szilasiova; Zuzana Gdovinova; Johan W Groothoff; Jitse P van Dijk
Journal:  Disabil Rehabil       Date:  2013-08-20       Impact factor: 3.033

Review 7.  The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.

Authors:  Marianne de Sèze; Alain Ruffion; Pierre Denys; Pierre-Alain Joseph; Brigitte Perrouin-Verbe
Journal:  Mult Scler       Date:  2007-03-15       Impact factor: 6.312

Review 8.  A UK consensus on the management of the bladder in multiple sclerosis.

Authors:  C J Fowler; J N Panicker; M Drake; C Harris; S C W Harrison; M Kirby; M Lucas; N Macleod; J Mangnall; A North; B Porter; S Reid; N Russell; K Watkiss; M Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 10.  Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.

Authors:  Crisanta I Tapia; Kristin Khalaf; Karina Berenson; Denise Globe; Michael Chancellor; Lesley K Carr
Journal:  Health Qual Life Outcomes       Date:  2013-01-31       Impact factor: 3.186

View more
  3 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

2.  [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis].

Authors:  Burkhard Domurath; Peter Flachenecker; Thomas Henze; Wolfgang Feneberg; Anna Brandt; Ines Kurze; Ruth Kirschner-Hermanns; Albert Kaufmann; Jörn Bremer; Manuela Vonthien; Kerstin Ratering; Christoph Schäfer; Will Nelson Vance; Paul Schmidt
Journal:  Nervenarzt       Date:  2021-01-05       Impact factor: 1.214

Review 3.  Pelvic Floor Dysfunctions and Their Rehabilitation in Multiple Sclerosis.

Authors:  Maddalena Sparaco; Simona Bonavita
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.